237 related articles for article (PubMed ID: 31476278)
1. Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap.
Gottlieb SL; Jerse AE; Delany-Moretlwe S; Deal C; Giersing BK
Sex Health; 2019 Sep; 16(5):426-432. PubMed ID: 31476278
[TBL] [Abstract][Full Text] [Related]
2. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
Semchenko EA; Tan A; Borrow R; Seib KL
Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148
[TBL] [Abstract][Full Text] [Related]
3. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
4. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.
Gottlieb SL; Ndowa F; Hook EW; Deal C; Bachmann L; Abu-Raddad L; Chen XS; Jerse A; Low N; MacLennan CA; Petousis-Harris H; Seib KL; Unemo M; Vincent L; Giersing BK;
Vaccine; 2020 Jun; 38(28):4362-4373. PubMed ID: 32359875
[TBL] [Abstract][Full Text] [Related]
5. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
[TBL] [Abstract][Full Text] [Related]
6. Exploitation of
Petousis-Harris H; Radcliff FJ
Front Immunol; 2019; 10():683. PubMed ID: 31024540
[TBL] [Abstract][Full Text] [Related]
7. Impact of meningococcal group B OMV vaccines, beyond their brief.
Petousis-Harris H
Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine.
Gulati S; Pennington MW; Czerwinski A; Carter D; Zheng B; Nowak NA; DeOliveira RB; Shaughnessy J; Reed GW; Ram S; Rice PA
mBio; 2019 Nov; 10(6):. PubMed ID: 31690678
[TBL] [Abstract][Full Text] [Related]
9. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.
Edwards JL; Jennings MP; Apicella MA; Seib KL
Crit Rev Microbiol; 2016 Nov; 42(6):928-41. PubMed ID: 26805040
[TBL] [Abstract][Full Text] [Related]
10. Neisseria gonorrhoeae vaccine development: hope on the horizon?
Edwards JL; Jennings MP; Seib KL
Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
[TBL] [Abstract][Full Text] [Related]
11. Vaccine research for gonococcal infections: where are we?
Jerse AE; Deal CD
Sex Transm Infect; 2013 Dec; 89 Suppl 4():iv63-8. PubMed ID: 24243883
[TBL] [Abstract][Full Text] [Related]
12. Promising developments in gonococcal vaccines.
Waltmann A; Chen JS; Duncan JA
Curr Opin Infect Dis; 2024 Feb; 37(1):63-69. PubMed ID: 38050729
[TBL] [Abstract][Full Text] [Related]
13. Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.
Matthias KA; Connolly KL; Begum AA; Jerse AE; Macintyre AN; Sempowski GD; Bash MC
J Infect Dis; 2022 Feb; 225(4):650-660. PubMed ID: 34498079
[TBL] [Abstract][Full Text] [Related]
14. Vaccine value profile for Neisseria gonorrhoeae.
Lyu Y; Choong A; Chow EPF; Seib KL; Marshall HS; Unemo M; de Voux A; Wang B; Miranda AE; Gottlieb SL; Mello MB; Wi T; Baggaley R; Marshall C; Abu-Raddad LJ; Abara WE; Chen XS; Ong JJ
Vaccine; 2023 Dec; ():. PubMed ID: 38123397
[TBL] [Abstract][Full Text] [Related]
15. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR.
Sevilla JP; Bloom DE; Cadarette D; Jit M; Lipsitch M
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12911-12919. PubMed ID: 30559203
[TBL] [Abstract][Full Text] [Related]
16. The potential impact of vaccination on the prevalence of gonorrhea.
Craig AP; Gray RT; Edwards JL; Apicella MA; Jennings MP; Wilson DP; Seib KL
Vaccine; 2015 Aug; 33(36):4520-4525. PubMed ID: 26192351
[TBL] [Abstract][Full Text] [Related]
17. Biological feasibility and importance of a gonorrhea vaccine for global public health.
Vincent LR; Jerse AE
Vaccine; 2019 Nov; 37(50):7419-7426. PubMed ID: 29680200
[TBL] [Abstract][Full Text] [Related]
18. Planning for a Gonococcal Vaccine: A Narrative Review of Vaccine Development and Public Health Implications.
Abara WE; Jerse AE; Hariri S; Kirkcaldy RD
Sex Transm Dis; 2021 Jul; 48(7):453-457. PubMed ID: 33201019
[TBL] [Abstract][Full Text] [Related]
19. Progress Toward a Gonococcal Vaccine: The Way Forward.
Russell MW; Jerse AE; Gray-Owen SD
Front Immunol; 2019; 10():2417. PubMed ID: 31681305
[TBL] [Abstract][Full Text] [Related]
20. [The therapeutic efficacy of a gonococcal vaccine].
Andreeva ZM; Bednova VN; Shevchenko NM; Malyshev AM; Danilenko TI
Vestn Dermatol Venerol; 1989; (11):53-5. PubMed ID: 2515676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
